Spirair is an early-stage company pioneering minimally invasive solutions for ENTs to advance care for their patients. The company is dedicated to developing a novel therapy for symptomatic nasal septal deviation (NSD) that supports and straightens minor deviations in the septum with a bioabsorbable implant.

spirair.com

Medical

Biotechnology

Health Care

South San Francisco, California, United States

Spirair announced it raised $12.8 Million in an initial filing from an offering of $23.6 Million

Company Information

Related People

Funding Insights

Spirair announced it raised $12.8 Million in an initial filing from an offering of $23.6 Million

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information